The European patent system: dealing with emerging technologies

In light of recent controversial patent decisions in biotechnology, this article argues that the current European patent examination and opposition procedures do not suffice to balance the patent system These procedures do not provide sufficient guidance for patent examiners to deal effectively with...

Full description

Saved in:
Bibliographic Details
Published inInnovation (Abingdon, England) Vol. 24; no. 1-2; pp. 85 - 105
Main Authors Kica, Evisa, Groenendijk, Nico
Format Journal Article
LanguageEnglish
Published Abingdon Taylor & Francis Group 01.01.2011
Taylor & Francis Ltd
Subjects
Online AccessGet full text
ISSN1351-1610
1469-8412
DOI10.1080/13511610.2011.571405

Cover

More Information
Summary:In light of recent controversial patent decisions in biotechnology, this article argues that the current European patent examination and opposition procedures do not suffice to balance the patent system These procedures do not provide sufficient guidance for patent examiners to deal effectively with the emerging life science technologies. The European Patent Office needs to instill more self-reflection into the patent system and foster interaction between the Office and patent stakeholders. In this respect, we propose that the EPO should establish an ex-ante, patent-granting advisory body that would consist of multidisciplinary staff drawn from various technical fields, and collaborate closely with the scientific community and other national bodies. It is expected that such an advisory body would provide an input to the existing patent system, since it would anticipate, control and reduce the possibility that patent examiners would issue low-quality patents with huge socio-economic consequences.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:1351-1610
1469-8412
DOI:10.1080/13511610.2011.571405